We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Regeneron Pharmaceuticals Stock

Invest in or calculate the value of your shares in Regeneron Pharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals is focused on the development of pharmaceutical products for the treatment of serious medical conditions.

About Regeneron Pharmaceuticals Stock

Founded

1988

Headquarters

Tarrytown, NY, US

Total Funding

8.9M

Industries

Software, Data and Analytics, Artificial Intelligence

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Regeneron Pharmaceuticals Management

Leadership team at Regeneron Pharmaceuticals

Vice President, Head, Regeneron Genetics Center

Aris Baras

Manager, Combination Products Engineering

Michael Selzer

Locked Features

Join now and verify your accreditation status to gain access to:

  • Regeneron Pharmaceuticals current valuation
  • Regeneron Pharmaceuticals stock price
  • Available deals in Regeneron Pharmaceuticals and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Regeneron Pharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like Regeneron Pharmaceuticals through EquityZen funds. These investments are made available by existing Regeneron Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Regeneron Pharmaceuticals stock?

Shareholders can sell their Regeneron Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."